Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Children and Adolescents

ABSTRACT

Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are both uncommon disorders that present with a microangiopathic hemolytic anemia and thrombocytopenia. Although for TTP, neurologic manifestations predominate, and in HUS renal dysfunction is virtually always present, there is significant overlap in their clinical presentation. In recent years, tremendous progress has been made in our understanding of the pathogenesis of these disorders. It is now apparent that there are subcategories of both TTP and HUS that can differ in their clinical manifestations, etiology, and management. For instance, although most cases of HUS are due to infection with organisms that produce Shiga-like toxin, other cases may be caused by defined genetic abnormalities. Similarly, TTP is usually caused by genetic or acquired deficiency of the ADAMTS13 enzyme; however, in other cases the relationship with this enzyme remains to be established. Management includes supportive care, plasma transfusions for genetic protein deficiencies, and plasma exchange transfusion for autoimmune TTP.

KEYWORDS

Thrombotic thrombocytopenic purpura (TTP) - hemolytic uremic syndrome (HUS) - microangiopathy - children

REFERENCES

• 1 Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen.  Thromb Res. 1985;  38 469-479
• 2 Moake J L. Thrombotic microangiopathies.  N Engl J Med. 2002;  347 589-600
• 3 Gasser C, Gautier E, Steck A, Siebenmann R E, Oechslin R. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia [in German].  Schweiz Med Wochenschr. 1955;  85 905-909
• 4 Lynn R M, O'Brien S J, Taylor C M et al.. Childhood hemolytic uremic syndrome, United Kingdom and Ireland.  Emerg Infect Dis. 2005;  11 590-596
• 5 Siegler R, Oakes R. Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.  Curr Opin Pediatr. 2005;  17 200-204
• 6 Konowalchuk J, Speirs J I, Stavric S. Vero response to a cytotoxin of Escherichia coli .  Infect Immun. 1977;  18 775-779
• 7 O'Brien A O, Lively T A, Chen M E, Rothman S W, Formal S B. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin.  Lancet. 1983;  1 702
• 8 Banatvala N, Griffin P M, Greene K D et al.. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings.  J Infect Dis. 2001;  183 1063-1070
• 9 Milford D V, Taylor C M, Guttridge B et al.. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: clinical and epidemiological aspects.  Arch Dis Child. 1990;  65 716-721
• 10 Kleanthous H, Smith H R, Scotland S M et al.. Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: microbiological aspects.  Arch Dis Child. 1990;  65 722-727
• 11 Gerber A, Karch H, Allerberger F, Verweyen H M, Zimmerhackl L B. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.  J Infect Dis. 2002;  186 493-500
• 12 Tozzi A E, Caprioli A, Minelli F et al.. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000.  Emerg Infect Dis. 2003;  9 106-108
• 13 Elliott E J, Robins-Browne R M, O'Loughlin E V et al.. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features.  Arch Dis Child. 2001;  85 125-131
• 14 Haeghebaert S, Vaillant V, Decludt B, Grimont P A. Surveillance of haemolytic uraemic syndrome in children under 15 years of age in France in 1998.  Euro Surveill. 2000;  5 68-73
• 15 Misselwitz J, Karch H, Bielazewska M et al.. Cluster of hemolytic-uremic syndrome caused by Shiga toxin-producing Escherichia coli O26:H11.  Pediatr Infect Dis J. 2003;  22 349-354
• 16 Varma J K, Greene K D, Reller M E et al.. An outbreak of Escherichia coli O157 infection following exposure to a contaminated building.  JAMA. 2003;  290 2709-2712
• 17 te Loo D M, Monnens L A, Der Velden T J et al.. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome.  Blood. 2000;  95 3396-3402
• 18 Karpman D, Papadopoulou D, Nilsson K et al.. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.  Blood. 2001;  97 3100-3108
• 19 Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic-uremic syndrome.  Semin Thromb Hemost. 2001;  27 207-213
• 20 Hughes A K, Ergonul Z, Stricklett P K, Kohan D E. Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression.  J Am Soc Nephrol. 2002;  13 2239-2245
• 21 Uchida H, Kiyokawa N, Horie H, Fujimoto J, Takeda T. The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome.  Pediatr Res. 1999;  45 133-137
• 22 Chandler W L, Jelacic S, Boster D R et al.. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.  N Engl J Med. 2002;  346 23-32
• 23 Bergstein J M, Riley M, Bang N U. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome.  N Engl J Med. 1992;  327 755-759
• 24 Ray P E, Liu X H. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome.  Pediatr Nephrol. 2001;  16 823-839
• 25 Tarr P I, Gordon C A, Chandler W L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.  Lancet. 2005;  365 1073-1086
• 26 Sakiri R, Ramegowda B, Tesh V L. Shiga toxin type 1 activates tumor necrosis factor-alpha gene transcription and nuclear translocation of the transcriptional activators nuclear factor-kappa B and activator protein-1.  Blood. 1998;  92 558-566
• 27 Nestoridi E, Tsukurov O, Kushak R I, Ingelfinger J R, Grabowski E F. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome.  J Thromb Haemost. 2005;  3 752-762
• 28 Ramegowda B, Tesh V L. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines.  Infect Immun. 1996;  64 1173-1180
• 29 Hughes A K, Stricklett P K, Schmid D, Kohan D E. Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells.  Kidney Int. 2000;  57 2350-2359
• 30 Lesesne J B, Rothschild N, Erickson B et al.. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.  J Clin Oncol. 1989;  7 781-789
• 31 Dlott J S, Danielson C F, Blue-Hnidy D E, McCarthy L J. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review.  Ther Apher Dial. 2004;  8 102-111
• 32 Ogier de Baulny H, Gerard M, Saudubray J M, Zittoun J. Remethylation defects: guidelines for clinical diagnosis and treatment.  Eur J Pediatr. 1998;  157(suppl 2) S77-S83
• 33 Cabrera G R, Fortenberry J D, Warshaw B L et al.. Hemolytic uremic syndrome associated with invasive Streptococcus pneumoniae infection.  Pediatrics. 1998;  101 699-703
• 34 Klein P J, Bulla M, Newman R A et al.. Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome.  Lancet. 1977;  2 1024-1025
• 35 Feld L G, Springate J E, Darragh R, Fildes R D. Pneumococcal pneumonia and hemolytic uremic syndrome.  Pediatr Infect Dis J. 1987;  6 693-695
• 36 Huang F Y, Lin D S. Pneumococcal meningitis complicated with hemolytic uremic syndrome: report of two cases.  Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998;  39 58-61
• 37 Noris M, Ruggenenti P, Perna A et al.. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura.  J Am Soc Nephrol. 1999;  10 281-293
• 38 Neumann H P, Salzmann M, Bohnert-Iwan B et al.. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries.  J Med Genet. 2003;  40 676-681
• 39 Warwicker P, Goodship T H, Donne R L et al.. Genetic studies into inherited and sporadic hemolytic uremic syndrome.  Kidney Int. 1998;  53 836-844
• 40 Richards A, Buddles M R, Donne R L et al.. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.  Am J Hum Genet. 2001;  68 485-490
• 41 Caprioli J, Bettinaglio P, Zipfel P F et al.. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.  J Am Soc Nephrol. 2001;  12 297-307
• 42 Dragon-Durey M A, Fremeaux-Bacchi V, Loirat C et al.. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.  J Am Soc Nephrol. 2004;  15 787-795
• 43 Kavanagh D, Kemp E J, Mayland E et al.. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16 2150-2155
• 44 Noris M, Brioschi S, Caprioli J et al.. Familial haemolytic uraemic syndrome and an MCP mutation.  Lancet. 2003;  362 1542-1547
• 45 Richards A, Kemp E J, Liszewski M K et al.. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.  Proc Natl Acad Sci USA. 2003;  100 12966-12971
• 46 Dragon-Durey M A, Loirat C, Cloarec S et al.. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16 555-563
• 47 Moake J L. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.  Arch Pathol Lab Med. 2002;  126 1430-1433
• 48 Levy G G, Motto D G, Ginsburg D. ADAMTS13 turns 3.  Blood. 2005;  106 11-17
• 49 Remuzzi G, Galbusera M, Noris M et al.. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  Blood. 2002;  100 778-785
• 50 Veyradier A, Obert B, Haddad E et al.. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.  J Pediatr. 2003;  142 310-317
• 51 Moghal N E, Brocklebank J T, Meadow S R. A review of acute renal failure in children: incidence, etiology and outcome.  Clin Nephrol. 1998;  49 91-95
• 52 Verweyen H M, Karch H, Allerberger F, Zimmerhackl L B. Enterohemorrhagic Escherichia coli (EHEC) in pediatric hemolytic-uremic syndrome: a prospective study in Germany and Austria.  Infection. 1999;  27 341-347
• 53 Brandt J R, Fouser L S, Watkins S L et al.. Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers.  J Pediatr. 1994;  125 519-526
• 54 Tarr P I, Fouser L S, Stapleton A E et al.. Hemolytic-uremic syndrome in a six-year-old girl after a urinary tract infection with Shiga-toxin-producing Escherichia coli O103:H2.  N Engl J Med. 1996;  335 635-638
• 55 Miller D P, Kaye J A, Shea K et al.. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.  Epidemiology. 2004;  15 208-215
• 56 Rangel J M, Sparling P H, Crowe C, Griffin P M, Swerdlow D L. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002.  Emerg Infect Dis. 2005;  11 603-609
• 57 Wong C S, Jelacic S, Habeeb R L, Watkins S L, Tarr P I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.  N Engl J Med. 2000;  342 1930-1936
• 58 Bell B P, Griffin P M, Lozano P et al.. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections.  Pediatrics. 1997;  100 E12
• 59 Lopez E L, Contrini M M, Devoto S et al.. Incomplete hemolytic-uremic syndrome in Argentinean children with bloody diarrhea.  J Pediatr. 1995;  127 364-367
• 60 Brandt J, Wong C, Mihm S et al.. Invasive pneumococcal disease and hemolytic uremic syndrome.  Pediatrics. 2002;  110 371-376
• 61 Brandt J R, Joseph M W, Fouser L S et al.. Cholelithiasis following Escherichia coli O157:H7-associated hemolytic uremic syndrome.  Pediatr Nephrol. 1998;  12 222-225
• 62 Constantinescu A R, Bitzan M, Weiss L S et al.. Non-enteropathic hemolytic uremic syndrome: causes and short-term course.  Am J Kidney Dis. 2004;  43 976-982
• 63 Siegler R L. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome.  J Pediatr. 1994;  125 511-518
• 64 Trompeter R S, Schwartz R, Chantler C et al.. Haemolytic-uraemic syndrome: an analysis of prognostic features.  Arch Dis Child. 1983;  58 101-105
• 65 Siegler R L, Pavia A T, Hansen F L, Christofferson R D, Cook J B. Atypical hemolytic-uremic syndrome: a comparison with postdiarrheal disease.  J Pediatr. 1996;  128 505-511
• 66 Onundarson P T, Rowe J M, Heal J M, Francis C W. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution.  Arch Intern Med. 1992;  152 791-796
• 67 Karch H, Bielaszewska M. Sorbitol-fermenting Shiga toxin-producing Escherichia coli O157:H(-) strains: epidemiology, phenotypic and molecular characteristics, and microbiological diagnosis.  J Clin Microbiol. 2001;  39 2043-2049
• 68 Zipfel P F, Neumann H P, Jozsi M. Genetic screening in haemolytic uraemic syndrome.  Curr Opin Nephrol Hypertens. 2003;  12 653-657
• 69 Fenton W, Rosenberg L. Disorders of propionate and methylmalonate metabolism. In: Scriver C, Baudet A, Sly W, Valle D Metaboloic and Molecular Basis of Inherited Disease. New York; McGraw-Hill 2001: 2165-2193
• 70 Ake J A, Jelacic S, Ciol M A et al.. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.  Pediatrics. 2005;  115 e673-e680
• 71 Dowling T C, Chavaillaz P A, Young D G et al.. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.  Antimicrob Agents Chemother. 2005;  49 1808-1812
• 72 Karmali M A. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.  J Infect Dis. 2004;  189 355-359
• 73 Bell B P, Goldoft M, Griffin P M et al.. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience.  JAMA. 1994;  272 1349-1353
• 74 Licht C, Weyersberg A, Heinen S et al.. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.  Am J Kidney Dis. 2005;  45 415-421
• 75 Nathanson S, Fremeaux-Bacchi V, Deschenes G. Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency.  Pediatr Nephrol. 2001;  16 554-556
• 76 Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children.  Pediatr Nephrol. 2003;  18 1095-1101
• 77 Ducloux D, Rebibou J M, Semhoun-Ducloux S et al.. Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis.  Transplantation. 1998;  65 1405-1407
• 78 Quan A, Sullivan E K, Alexander S R. Recurrence of hemolytic uremic syndrome after renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study.  Transplantation. 2001;  72 742-745
• 79 Cheong H I, Lee B S, Kang H G et al.. Attempted treatment of factor H deficiency by liver transplantation.  Pediatr Nephrol. 2004;  19 454-458
• 80 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc NY Pathol Soc. 1924;  24 21-24
• 81 Colige A, Sieron A L, Li S W et al.. Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene.  Am J Hum Genet. 1999;  65 308-317
• 82 Dagoneau N, Benoist-Lasselin C, Huber C et al.. ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome.  Am J Hum Genet. 2004;  75 801-806
• 83 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
• 84 Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis, I: a factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency.  Blood. 1960;  16 943-957
• 85 Upshaw Jr J D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia.  N Engl J Med. 1978;  298 1350-1352
• 86 Schneppenheim R, Budde U, Oyen F et al.. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.  Blood. 2003;  101 1845-1850
• 87 Jubinsky P T, Moraille R, Tsai H M. Thrombotic thrombocytopenic purpura in a newborn.  J Perinatol. 2003;  23 85-87
• 88 Kinoshita S, Yoshioka A, Park Y D et al.. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura.  Int J Hematol. 2001;  74 101-108
• 89 Chintagumpala M M, Hurwitz R L, Moake J L, Mahoney D H, Steuber C P. Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission.  J Pediatr. 1992;  120 49-53
• 90 Matsumoto M, Kokame K, Soejima K et al.. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.  Blood. 2004;  103 1305-1310
• 91 Schiff D E, Roberts W D, Willert J, Tsai H M. Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency.  J Pediatr Hematol Oncol. 2004;  26 535-538
• 92 Burle S, Passi G R, Salgia P, Modi A. Thrombotic thrombocytopenic purpura.  Indian Pediatr. 2004;  41 277-279
• 93 Elias M, Horowitz J, Tal I, Kohn D, Flatau E. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in three siblings.  Arch Dis Child. 1988;  63 644-646
• 94 Buyukavci M, Olgun H, Kertmen B, Tan H, Ceviz N. Ventricular tachycardia as a presenting symptom in a child with thrombotic thrombocytopenic purpura.  Thromb Haemost. 2004;  91 198-200
• 95 Allford S L, Harrison P, Lawrie A S et al.. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura.  Br J Haematol. 2000;  111 1215-1222
• 96 Barbot J, Costa E, Guerra M et al.. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease.  Br J Haematol. 2001;  113 649-651
• 97 Savasan S, Lee S K, Ginsburg D, Tsai H M. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity.  Blood. 2003;  101 4449-4451
• 98 Haberle J, Kehrel B, Ritter J et al.. New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review.  Eur J Pediatr. 1999;  158 883-887
• 99 Cohen J A, Brecher M E, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura.  J Clin Apher. 1998;  13 16-19
• 100 Furlan M, Robles R, Galbusera M et al.. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
• 101 Furlan M, Robles R, Solenthaler M et al.. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1997;  89 3097-3103
• 102 Mannucci P M, Lombardi R, Lattuada A et al.. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.  Blood. 1989;  74 978-983
• 103 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 104 van Mourik J A, Boertjes R, Huisveld I A et al.. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation.  Blood. 1999;  94 179-185
• 105 Savasan S, Taub J W, Buck S et al.. Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von Willebrand factor multimers and von Willebrand factor-cleaving protease.  J Pediatr Hematol Oncol. 2001;  23 364-367
• 106 Katz J A, Moake J L, McPherson P D et al.. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma.  Blood. 1989;  73 1851-1858
• 107 Tsai H M, Sarode R, Downes K A. Ultralarge von Willebrand factor multimers and normal ADAMTS13 activity in the umbilical cord blood.  Thromb Res. 2002;  108 121-125
• 108 Weinstein M J, Blanchard R, Moake J L, Vosburgh E, Moise K. Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura.  Br J Haematol. 1989;  72 68-72
• 109 Hellstrom-Westas L, Ley D, Berg A C, Kristoffersson A C, Holmberg L. VWF-cleaving protease (ADAMTS13) in premature infants.  Acta Paediatr. 2005;  94 205-210
• 110 Kavakli K, Canciani M T, Mannucci P M. Plasma levels of the von Willebrand factor-cleaving protease in physiological and pathological conditions in children.  Pediatr Hematol Oncol. 2002;  19 467-473
• 111 Mannucci P M, Canciani M T, Forza I et al.. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.  Blood. 2001;  98 2730-2735
• 112 Schmugge M, Dunn M S, Amankwah K S et al.. The activity of the von Willebrand factor cleaving protease ADAMTS-13 in newborn infants.  J Thromb Haemost. 2004;  2 228-233
• 113 Assink K, Schiphorst R, Allford S et al.. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.  Kidney Int. 2003;  63 1995-1999
• 114 Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura.  Semin Hematol. 2004;  41 34-40
• 115 Schneppenheim R, Budde U, Hassenpflug W, Obser T. Severe ADAMTS-13 deficiency in childhood.  Semin Hematol. 2004;  41 83-89
• 116 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost. 1999;  81 8-13
• 117 Kentouche K, Budde U, Furlan M et al.. Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma.  Acta Paediatr. 2002;  91 1056-1059
• 118 Moake J L, Byrnes J J, Troll J H et al.. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1985;  65 1232-1236
• 119 Moake J, Chintagumpala M, Turner N et al.. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura.  Blood. 1994;  84 490-497
• 120 Brunner H I, Freedman M, Silverman E D. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood.  Arthritis Rheum. 1999;  42 2346-2355
• 121 Chak W K, Lam D S, Lo W H, Hui C M, Wong S N. Thrombotic thrombocytopenic purpura as a rare complication in childhood systemic lupus erythematosus: case report and literature review.  Hong Kong Med J. 2003;  9 363-368
• 122 Gungor T, Furlan M, Lämmle B, Kuhn F, Seger R A. Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus.  Rheumatology (Oxford). 2001;  40 940-942
• 123 Studt J D, Hovinga J A, Radonic R et al.. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins.  Blood. 2004;  103 4195-4197
• 124 Elliott M A, Nichols Jr W L, Plumhoff E A et al.. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.  Mayo Clin Proc. 2003;  78 421-430
• 125 Fuge R, Bird J M, Fraser A et al.. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation.  Br J Haematol. 2001;  113 58-64
• 126 Ruutu T, Hermans J, Niederwieser D et al.. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT).  Br J Haematol. 2002;  118 1112-1119
• 126a Uderzo C, Funagalii M, DeLorenzo P et al.. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation.  Bone Marrow Transplant. 2000;  26 1005-1009
• 127 Arai S, Allan C, Streiff M et al.. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.  Hematol J. 2001;  2 292-299
• 128 van der Plas R M, Schiphorst M E, Huizinga E G et al.. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.  Blood. 1999;  93 3798-3802
• 129 Ashida A, Nakamura H, Yoden A et al.. Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw-Schulman syndrome.  Am J Hematol. 2002;  71 318-322
• 130 Horton T M, Stone J D, Yee D et al.. Case series of thrombotic thrombocytopenic purpura in children and adolescents.  J Pediatr Hematol Oncol. 2003;  25 336-339
• 131 Robson W L, Tsai H M. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy.  Pediatrics. 2002;  109 322-325
• 132 Hunt B J, Lämmle B, Nevard C H, Haycock G B, von Furlan M. Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome.  Thromb Haemost. 2001;  85 975-978
• 133 Rock G, Shumak K, Nair R. A study of plasma exchange in TTP. The Canadian Apheresis Study Group.  Prog Clin Biol Res. 1990;  337 125-127
• 134 Bell W R, Braine H G, Ness P M, Kickler T S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.  N Engl J Med. 1991;  325 398-403
• 135 George J N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Blood. 2000;  96 1223-1229
• 136 Lara Jr P N, Coe T L, Zhou H et al.. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Am J Med. 1999;  107 573-579
• 137 George J N, Sadler J E, Lämmle B. Platelets: thrombotic thrombocytopenic purpura.  Hematology (Am Soc Hematol Educ Program). 2002;  315-334
• 138 Perdue J J, Chandler L K, Vesely S K et al.. Unintentional platelet removal by plasmapheresis.  J Clin Apher. 2001;  16 55-60
• 139 Coppo P, Bussel A, Charrier S et al.. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome.  Medicine (Baltimore). 2003;  82 27-38
• 140 Bobbio-Pallavicini E, Gugliotta L, Centurioni R et al.. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP.  Haematologica. 1997;  82 429-435
• 141 Jayabose S, Levendoglu-Tugal O, Ozkayanak M F et al.. Use of vincristine and cyclosporine in childhood thrombotic thrombocytopenic purpura.  J Pediatr Hematol Oncol. 2003;  25 421-425
• 142 Welborn J L, Emrick P, Acevedo M. Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresis.  Am J Hematol. 1990;  35 18-21
• 143 Hand J P, Lawlor E R, Yong C K, Davis J H. Successful use of cyclosporine A in the treatment of refractory thrombotic thrombocytopenic purpura.  Br J Haematol. 1998;  100 597-599
• 144 Kondo H, Imamura T. Effects of intravenous immunoglobulin in a patient with intermittent thrombotic thrombocytopenic purpura.  Br J Haematol. 2000;  108 880-882
• 145 Dervenoulas J, Tsirigotis P, Bollas G et al.. Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases.  Acta Haematol. 2001;  105 204-208
• 146 Koulova L, Alexandrescu D, Dutcher J P et al.. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.  Am J Hematol. 2005;  78 49-54
• 147 Fakhouri F, Vernant J P, Veyradier A et al.. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13 deficient-thrombotic thrombocytopenic purpura: a study of 11 cases.  Blood. 2005;  , In press
• 148 Crowther M A, Heddle N, Hayward C P, Warkentin T, Kelton J G. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura.  Ann Intern Med. 1996;  125 294-296
• 149 Thompson C E, Damon L E, Ries C A, Linker C A. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic.  Blood. 1992;  80 1890-1895
• 150 Schwartz J, Eldor A, Szold A. Laparoscopic splenectomy in patients with refractory or relapsing thrombotic thrombocytopenic purpura.  Arch Surg. 2001;  136 1236-1238